Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1990 1
1991 1
1993 2
1994 1
1995 4
1997 2
1998 1
1999 1
2000 3
2001 3
2002 3
2003 4
2004 2
2005 2
2006 4
2007 4
2008 3
2009 1
2010 4
2011 6
2012 2
2013 6
2014 13
2015 4
2016 10
2017 12
2018 10
2019 12
2020 23
2021 12
2022 12
2023 15
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Results by year

Filters applied: . Clear all
Page 1
Combined hepatocellular-cholangiocarcinoma: An update.
Beaufrère A, Calderaro J, Paradis V. Beaufrère A, et al. J Hepatol. 2021 May;74(5):1212-1224. doi: 10.1016/j.jhep.2021.01.035. Epub 2021 Feb 3. J Hepatol. 2021. PMID: 33545267 Review.
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a tumour that exhibits both hepatocytic and biliary differentiation. Classical risk factors for hepatocellular carcinoma (HCC) seem to also predispose patients to the development of cHCC-C …
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a tumour that exhibits both hepatocytic and biliary differenti …
Tumor-associated macrophages in liver cancer: From mechanisms to therapy.
Cheng K, Cai N, Zhu J, Yang X, Liang H, Zhang W. Cheng K, et al. Cancer Commun (Lond). 2022 Nov;42(11):1112-1140. doi: 10.1002/cac2.12345. Epub 2022 Sep 7. Cancer Commun (Lond). 2022. PMID: 36069342 Free PMC article. Review.
In addition, macrophages in the TME interact with other immune cells by directing cell-to-cell contact or secreting various effector molecules. Similarly, tumor cells combined with other immune cells can drive macrophage recruitment and polarization. ...In this review, we …
In addition, macrophages in the TME interact with other immune cells by directing cell-to-cell contact or secreting various effector molecul …
Update on hepatocellular carcinoma: Pathologists' review.
El Jabbour T, Lagana SM, Lee H. El Jabbour T, et al. World J Gastroenterol. 2019 Apr 14;25(14):1653-1665. doi: 10.3748/wjg.v25.i14.1653. World J Gastroenterol. 2019. PMID: 31011252 Free PMC article. Review.
Histopathologic diversity and several distinct histologic subtypes of hepatocellular carcinoma (HCC) are well-recognized. Recent advances in molecular pathology and growing knowledge about the biology associated with distinct histologic features and immuno-profile i …
Histopathologic diversity and several distinct histologic subtypes of hepatocellular carcinoma (HCC) are well-recognized. Rece …
Clinical treatment of cholangiocarcinoma: an updated comprehensive review.
Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, Longarini R, Stagno AM, Cristoferi L, Ciaccio A, Cortinovis DL, Invernizzi P, Massironi S. Elvevi A, et al. Ann Hepatol. 2022 Sep-Oct;27(5):100737. doi: 10.1016/j.aohep.2022.100737. Epub 2022 Jul 7. Ann Hepatol. 2022. PMID: 35809836 Free article. Review.
Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms of the bile ducts and represents the second most common hepatic cancer after hepatocellular carcinoma; it is sub-classified as intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cho …
Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms of the bile ducts and represents the second most common hepatic cancer …
Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Rizvi S, Gores GJ. Rizvi S, et al. Gastroenterology. 2013 Dec;145(6):1215-29. doi: 10.1053/j.gastro.2013.10.013. Epub 2013 Oct 15. Gastroenterology. 2013. PMID: 24140396 Free PMC article. Review.
Cholangiocarcinomas (CCAs) are hepatobiliary cancers with features of cholangiocyte differentiation; they can be classified anatomically as intrahepatic CCA (iCCA), perihilar CCA (pCCA), or distal CCA. ...
Cholangiocarcinomas (CCAs) are hepatobiliary cancers with features of cholangiocyte differentiation; they can be classified anatomica …
Systemic therapies for intrahepatic cholangiocarcinoma.
Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Kelley RK, et al. J Hepatol. 2020 Feb;72(2):353-363. doi: 10.1016/j.jhep.2019.10.009. J Hepatol. 2020. PMID: 31954497 Review.
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. ...The established standard of care includes first-line (gemcitabine and cisplatin), second-line (FOLFOX) and adjuvant (capecitabine) systemic chemotherapy. Comp …
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. ...The established st …
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice.
Pinter M, Scheiner B, Pinato DJ. Pinter M, et al. Lancet Gastroenterol Hepatol. 2023 Aug;8(8):760-770. doi: 10.1016/S2468-1253(23)00147-4. Epub 2023 Jun 14. Lancet Gastroenterol Hepatol. 2023. PMID: 37327807 Review.
Systemic therapy for advanced hepatocellular carcinoma has expanded at an unprecedented pace over the past 5 years. ...We discuss the challenges in individuals with rare histological subtypes of primary liver cancer, including combined hepatocellular- …
Systemic therapy for advanced hepatocellular carcinoma has expanded at an unprecedented pace over the past 5 years. ...We disc …
Heterogeneity of liver cancer and personalized therapy.
Li L, Wang H. Li L, et al. Cancer Lett. 2016 Sep 1;379(2):191-7. doi: 10.1016/j.canlet.2015.07.018. Epub 2015 Jul 23. Cancer Lett. 2016. PMID: 26213370 Review.
Liver cancer is an extraordinarily heterogeneous malignant disease among the tumors that have so far been identified. Hepatocellular carcinoma (HCC) arises most frequently in the setting of chronic liver inflammation and fibrosis, and takes a variety of course in in …
Liver cancer is an extraordinarily heterogeneous malignant disease among the tumors that have so far been identified. Hepatocellular …
Immune checkpoint therapy in liver cancer.
Xu F, Jin T, Zhu Y, Dai C. Xu F, et al. J Exp Clin Cancer Res. 2018 May 29;37(1):110. doi: 10.1186/s13046-018-0777-4. J Exp Clin Cancer Res. 2018. PMID: 29843754 Free PMC article. Review.
Preclinical and clinical studies show immune checkpoint therapy provides survival benefit for greater numbers of patients with liver cancer, including hepatocellular carcinoma and cholangiocarcinoma, two main primary liver cancers. ...In this review, we summa …
Preclinical and clinical studies show immune checkpoint therapy provides survival benefit for greater numbers of patients with liver cancer, …
175 results